ECSP045200A - ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS - Google Patents
ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOSInfo
- Publication number
- ECSP045200A ECSP045200A EC2004005200A ECSP045200A ECSP045200A EC SP045200 A ECSP045200 A EC SP045200A EC 2004005200 A EC2004005200 A EC 2004005200A EC SP045200 A ECSP045200 A EC SP045200A EC SP045200 A ECSP045200 A EC SP045200A
- Authority
- EC
- Ecuador
- Prior art keywords
- alcoxipropanoicos
- imidazolil
- acids
- alkyl
- hydrogen
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- -1 aromatic heterocycle Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de acuerdo con la fórmula (I) en la que n es 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7, R8 y R9 se selecciona independientemente entre hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5 y R8 son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patologías asociadas con la deposición de fibrina.The compounds according to formula (I) in which n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, heterocycle, aromatic heterocycle, aryl or hydrogen and each of R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, they are novel. These compounds are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045200A true ECSP045200A (en) | 2004-08-27 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005200A ECSP045200A (en) | 2002-01-22 | 2004-07-22 | ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (en) |
| JP (1) | JP2005520811A (en) |
| KR (1) | KR20040077775A (en) |
| CN (1) | CN1620291A (en) |
| AP (1) | AP2004003084A0 (en) |
| AR (1) | AR038197A1 (en) |
| BR (1) | BR0307016A (en) |
| CA (1) | CA2472238A1 (en) |
| EA (1) | EA200400716A1 (en) |
| EC (1) | ECSP045200A (en) |
| HR (1) | HRP20040659A2 (en) |
| IL (1) | IL162677A0 (en) |
| IS (1) | IS7310A (en) |
| MA (1) | MA27167A1 (en) |
| MX (1) | MXPA04006573A (en) |
| NO (1) | NO20043457L (en) |
| OA (1) | OA12756A (en) |
| PA (1) | PA8563501A1 (en) |
| PE (1) | PE20030929A1 (en) |
| PL (1) | PL371487A1 (en) |
| TN (1) | TNSN04121A1 (en) |
| TW (1) | TW200302094A (en) |
| UY (1) | UY27615A1 (en) |
| WO (1) | WO2003061652A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| CA2604912A1 (en) * | 2005-04-18 | 2006-10-26 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| AU2009310841A1 (en) | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having TAFIa inhibitory activity |
| AU2009322342A1 (en) * | 2008-12-05 | 2011-06-30 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| KR20130006620A (en) * | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | Cyclopropanecarboxylic acid derivative |
| SG10201502026XA (en) | 2010-03-18 | 2015-05-28 | Daiichi Sankyo Co Ltd | Cycloalkyl-substituted imidazole derivative |
| RU2015156612A (en) | 2013-06-10 | 2017-07-17 | Санофи | MACROCYCLIC DERIVATIVES OF UREA AS TAFIA INHIBITORS, THEIR PRODUCTION AND USE thereof AS PHARMACEUTICAL PRODUCTS |
| US20190117624A1 (en) | 2016-03-29 | 2019-04-25 | Daiichi Sankyo Company, Limited | Therapeutic agent for inflammatory bowel diseases |
| MY202326A (en) | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (en) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| PT1311488E (en) * | 2000-08-17 | 2009-12-30 | Pfizer Ltd | Substituted imidazoles as tafia inhibitors |
-
2003
- 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
- 2003-01-10 EA EA200400716A patent/EA200400716A1/en unknown
- 2003-01-10 IL IL16267703A patent/IL162677A0/en unknown
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/en active Pending
- 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/en not_active Ceased
- 2003-01-10 PL PL03371487A patent/PL371487A1/en unknown
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/en unknown
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Ceased
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/en not_active IP Right Cessation
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/en active Pending
- 2003-01-10 HR HR20040659A patent/HRP20040659A2/en not_active Application Discontinuation
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-16 TW TW092100889A patent/TW200302094A/en unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/en not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/en not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/en unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/en unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/en unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/en unknown
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/en unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL162677A0 (en) | 2005-11-20 |
| UY27615A1 (en) | 2003-08-29 |
| IS7310A (en) | 2004-06-14 |
| TNSN04121A1 (en) | 2006-06-01 |
| KR20040077775A (en) | 2004-09-06 |
| WO2003061652A8 (en) | 2004-09-10 |
| TW200302094A (en) | 2003-08-01 |
| AP2004003084A0 (en) | 2004-09-30 |
| PE20030929A1 (en) | 2003-11-05 |
| EP1467731A1 (en) | 2004-10-20 |
| MXPA04006573A (en) | 2004-10-04 |
| JP2005520811A (en) | 2005-07-14 |
| CN1620291A (en) | 2005-05-25 |
| AR038197A1 (en) | 2005-01-05 |
| MA27167A1 (en) | 2005-01-03 |
| BR0307016A (en) | 2004-11-03 |
| HRP20040659A2 (en) | 2004-10-31 |
| NO20043457L (en) | 2004-08-19 |
| WO2003061652A1 (en) | 2003-07-31 |
| PL371487A1 (en) | 2005-06-13 |
| CA2472238A1 (en) | 2003-07-31 |
| OA12756A (en) | 2006-07-03 |
| PA8563501A1 (en) | 2004-08-31 |
| EA200400716A1 (en) | 2004-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27522A1 (en) | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | |
| NO20005237D0 (en) | Heterocyclic substituted amides used as calpain inhibitors | |
| ES2184280T3 (en) | INDOL COMPOUNDS AS COX-2 'INHIBITORS. | |
| CY1107903T1 (en) | ACYLAMINOTHIACEALE PRODUCTS AND THEIR USE AS BETA-AMYLOID INHIBITORS | |
| PE20050999A1 (en) | NOVEL KETOAMIDES WITH CYCLIC P4 AS INHIBITORS OF NS3 SERINE PROTEASE FROM HEPATITIS C VIRUS | |
| NO20071642L (en) | N-Benzenesulfonyl-substituted anilino-pyrimidine analogs | |
| PE20070078A1 (en) | MACROCICLIC HETEROCYCLIC COMPOUNDS AS ASPARTILE PROTEASE INHIBITORS | |
| ATE404538T1 (en) | TETRAHYDROPYRANYLCYCLOPENTYLTETRAHYDROISOCHINO-LINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | |
| ECSP045369A (en) | DERIVATIVES OF N- [PHENYL (PIPERIDIN-2-IL) METIL] BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| PE20050226A1 (en) | ARIL-HETEROAROMATIC PRODUCTS AND COMPOSITIONS CONTAINING THEM | |
| CO6150147A2 (en) | DERIVED FROM 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS | |
| CO5580762A2 (en) | LIPOXINE A4 ANALOGS | |
| AR042362A1 (en) | DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| UY27615A1 (en) | ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS | |
| PE20050231A1 (en) | DERIVATIVES OF PIPERIDINIUM AND PYRROLIDINIUM AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR | |
| PE20040528A1 (en) | PEPTIDE-DEFORMYLASE INHIBITORS | |
| MXPA04005940A (en) | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases. | |
| PE20050120A1 (en) | KITCHENS WITH A MODIFIED LACTONE RING | |
| AR040140A1 (en) | CAMPTOTECHINE ESTERS DERIVATIVES IN POSITION 20 | |
| PE20030611A1 (en) | LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS | |
| DE60124717D1 (en) | ARYL-SULFONAMIDES AS SEROTONINE ANTAGONISTS FOR THE TREATMENT OF GRAVITY | |
| AR053339A1 (en) | COMPOSITIONS FOR THE TREATMENT OF HAIR AND / OR LEATHER HAIR | |
| DOP2003000564A (en) | ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS | |
| BRPI0508471A (en) | difluoroethoxy substituted hydroxy-6-phenylphenanthridines | |
| PE20010165A1 (en) | DERIVATIVES OF 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETILCROMANO AS ANTAGONISTS OF SUBSTANCE P |